SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is captivating the market after silver reached historic price levels, sparking a heated debate among traders about its sustainability. While some bulls anticipate continued parabolic gains driven by industrial demand and geopolitical factors, a significant bearish contingent warns of an imminent pullback, pointing to extreme volatility and potential market manipulation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending sharply lower following reports of a proposed Trump administration policy to keep Medicare Advantage rates largely flat for next year, significantly below analyst expectations. This potential regulatory headwind has sparked widespread debate and concerns over market manipulation, with many investors questioning its impact on future profitability and whether the sell-off presents a buying opportunity ahead of its earnings report.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a trending topic, propelled by an exclusive AI licensing partnership for its Engagement Language Model in Africa, fueling immense community excitement. Traders are actively discussing the potential for a significant short squeeze, pushing for triple-digit price targets amidst warnings from bears about its rapid ascent.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending due to proposed flat Medicare Advantage payment rates for 2027 by CMS, which are significantly below analyst expectations and signal potential margin pressure for MA-heavy insurers. This news has sparked a sector-wide re-evaluation and a notable sell-off, despite recent reaffirmations of guidance and improved star ratings for some of its plans. The community is actively debating whether this is an overblown reaction, similar to past regulatory shocks, or if it indicates a more sustained challenge to profitability.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is actively trending as the community eagerly anticipates a significant NASA Lunar Terrain Vehicle (LTV) contract award, positioning the company as a leading contender in the burgeoning lunar economy. Investors are closely watching for this pivotal announcement, alongside the company's crucial role in communications and data tracking for the upcoming Artemis II mission, fueling speculation about its future trajectory within the space sector.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as physical silver prices surge to historic highs, driven by growing industrial demand and persistent supply deficits, prompting discussions of a significant market re-rating for miners. The community is buzzing with anticipation for AG to rapidly catch up to these soaring spot prices, especially following its recent substantial production increase and a doubled dividend, despite ongoing market volatility.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending following a significant $1.6 billion U.S. government investment through the CHIPS Program, coupled with a $1.5 billion private placement, aimed at securing a domestic rare earth supply chain. The community is actively discussing this strategic backing as a catalyst for substantial long-term growth and reduced reliance on foreign sources, drawing comparisons to past government-supported entities. Despite an initial price surge followed by a notable pullback, discussions persist about the long-term potential, short covering, and strategic importance of rare earth minerals for national security, though some voice concerns about valuation and 'pump' dynamics.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to its significant acquisition of SkyWater Technology, a strategic move many interpret as building a vertically integrated quantum computing platform and securing a domestic supply chain. While proponents view this as accelerating IonQ's roadmap in the critical quantum race, the community is actively debating concerns over potential dilution and the immediate market reaction, leading to notable volatility.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS Health is trending as the market weighs mixed signals for the healthcare sector. While proposed flat rates for Medicare Advantage initially caused broad concern, CVS's recent Investor Day provided an optimistic outlook with raised profit forecasts and strategic growth initiatives, driving a wave of bullish analyst upgrades. The community is actively discussing the company's resilient potential, anticipating further upside supported by its diversified model.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics (CVKD) is attracting significant attention due to its expanding pipeline with acquired anticoagulant assets and ongoing advancements for its lead candidate, Tecarfarin, which holds FDA Fast Track and Orphan Drug designations. The community is sharply divided, with strong enthusiasm for its potential to modernize anticoagulation contrasting with skepticism around cash runway, dilution concerns, and allegations of promotional bot activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The verbal ruling was delivered on January 15, without written reasons, the company said.</li><li>The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued.</li><li>The company does not expect the ruling to impact outcomes of its patent infringement cases against Moderna.</li></ul>Arbutus Biopharma Corp. (ABUS) stock crashed more than 18% on Friday after the European Patent Office (EPO) revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.This marked the <a href="https://stocktwits.com/symbol/ABUS">ABUS stock’s</a> biggest intraday decline since July 2020.The verbal ruling was delivered on January 15 without written reasons, Arbutus said. The EPO ruling reverses two earlier decisions that had upheld an amended version of the patent EP 2279254. According to Google Patents, it covers “Novel lipid formulations for nucleic acid delivery.”The company said it disagrees with the outcome and plans to seek a review by the Enlarged Board of Appeal once the written ruling is issued. Arbutus acknowledged that the decision could affect certain European legal actions against Moderna, including a case in Switzerland and a proceeding before the Unified Patent Court in which the patent is being asserted.<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> (MRNA) jumped 7%, while <a href="https://stocktwits.com/symbol/MRK">Merck</a> (MRK) traded 2% lower.<h2 class="st-heading-2">Impact Outside Europe</h2>Arbutus stressed that the revocation was based on the EPO’s “added matter” standard, which does not apply in other jurisdictions.As a result, the company does not expect the ruling to impact the timing or potential outcomes of its patent infringement cases against Moderna in the United States, Japan, or Canada, a separate Unified Patent Court case not involving the patent, or its ongoing litigation against Pfizer and BioNTech in the U.S.<h2 class="st-heading-2">Retail Reaction</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/ABUS_jpg_f665738876.webp" alt="ABUS.jpg">One user sees the drop as an opportunity to take up fresh positions.<stembedurl>https://stocktwits.com/LS172/message/642060814</stembedurl>One user said it’s all noise and nothing has changed ‘other than the bad headline’.<stembedurl>https://stocktwits.com/EdDwg/message/642040053</stembedurl>The stock has gained around 20% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-jfbr-stock-surge-today/cmUlvsnR4B0">Why This Penny Stock Is On Track To Gain For First Time In 10 Sessions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Plug Power said it was impacted by the speed and development of hydrogen economy.

ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe?

The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.

Equity

Arbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Here's Why

Arbutus Biopharma (NASDAQ:ABUS) Shares Gap Down - Time to Sell...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200 Day Moving Average - What's Next...

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arbutus Biopharma (NASDAQ:ABUS) Shares Up 6% - Still a Buy?

Arbutus Biopharma (NASDAQ:ABUS) Trading 6% Higher - Here's What Happened...

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - What's Next...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4% - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Trading Down 6.4% - Time to Sell...

Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP

Two Seas Capital LP increased its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 10.3% during the 2nd quarter, according to its most recent Form 13F filing with...

Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital

Chardan Capital reiterated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday...

Arbutus Biopharma (NASDAQ:ABUS) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Arbutus Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday...

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

No change

25 bps cut

25 bps hike

Note sure, just watching

The Fed announces its rate decision this Wednesday.

Markets are pricing in a ~99% chance of no change at this week’s Fed decision, according to prediction markets. $SPY $QQQ 

FOMC on Wednesday, what do you think the Fed will decide?

Current Price	$4.08
Prev Close	$4.06
Open	$4.05
Dividend Yield	0.00%
50-Day Moving Average	$4.53
Beta	0.84
Avg. Volume	1.32M
PE Ratio	-18.30

52-Week High	$5.10
52-Week Low	$2.71
Market Capitalization	$780.84M
EPS (Annual)	-$0.3767
Price to Book	10.07
Revenue Per Employee	$140,250.00
Enterprise Value/EBITDA	N/A

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABUS News

ABUSArbutus Biopharma Corp